Steviol

Steviol is a diterpenoid aglycone and the core metabolic product of steviol glycosides, including stevioside and rebaudioside A, derived from Stevia rebaudiana. It exerts biological effects primarily by modulating cAMP signaling, inhibiting key DNA enzymes, and interacting with bitter taste receptors (TAS2Rs) and TRPA1 channels.

Origin & History

Steviol is the aglycone of steviol glycosides, derived from the leaves of Stevia rebaudiana, a perennial herb native to South America. It is produced through hydrolysis of stevioside or other steviol glycosides during digestion or extraction processes, belonging to the chemical class of ent-kaurene diterpenoids.

Historical & Cultural Context

Stevia rebaudiana leaves have been used for centuries in Guarani traditional medicine in Paraguay and South America as a sweetener and for hypoglycemic effects in type 2 diabetes. Historical use dates to pre-Columbian times and continues in modern herbal practices.

Health Benefits

• May support healthy blood pressure levels - meta-analysis found stevioside (not rebaudioside A) reduced systolic BP, though effects were small with high heterogeneity (PMID: 25412840)
• Potential anti-cancer properties - in-vitro studies show steviol inhibits DNA polymerases/topoisomerase II and triggers apoptosis in colon/breast/GI cancer cells (preliminary evidence)
• Anti-inflammatory effects - steviol inhibits NF-κB, TNF-α/IL-1β in LPS-stimulated monocytes and downregulates liver inflammation genes (preliminary evidence)
• Enhanced glucose uptake - increases PI3K/Akt phosphorylation and GLUT translocation in muscle cells, mimicking insulin action (preliminary evidence)
• Weight maintenance support - daily stevia consumption in healthy adults showed no glycemic impact but aided weight maintenance (limited clinical evidence)

How It Works

Steviol and its glycoside stevioside activate cAMP-mediated signaling pathways, enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which contributes to its antidiabetic potential. Steviol directly inhibits DNA polymerases alpha/beta and topoisomerase II, disrupting cancer cell replication in in-vitro models. Additionally, steviol interacts with bitter taste receptors (TAS2Rs) and TRPA1 channels in enteroendocrine cells, potentially influencing GLP-1 secretion and downstream glycemic regulation.

Scientific Research

A 2019 systematic review and meta-analysis of 9 RCTs (n=462) found no significant effects of steviol glycosides on fasting blood glucose or insulin levels (PMID: 31438580). Another meta-analysis showed stevioside may reduce systolic BP with small effects (PMID: 25412840), while a 2024 meta-analysis confirmed no effect on glucose metabolism (PMID: 38512280).

Clinical Summary

A 2014 meta-analysis (PMID: 25412840) of multiple RCTs found stevioside supplementation reduced systolic blood pressure modestly, though effect sizes were small and heterogeneity was high, limiting conclusions; rebaudioside A showed no significant effect. Human trials using doses of 750–1500 mg/day of stevioside over 1–2 years in hypertensive patients reported modest but statistically significant reductions in systolic and diastolic BP. Anticancer and enzyme-inhibition data remain confined to in-vitro and animal models, with no confirmed human clinical trials establishing efficacy. Overall, the evidence base is preliminary, and steviol's clinical profile is largely inferred from stevioside pharmacology since steviol itself is a gut-generated metabolite not typically administered directly.

Nutritional Profile

Steviol is the core aglycone diterpene compound derived from the metabolic breakdown of steviol glycosides (e.g., stevioside, rebaudioside A) found in Stevia rebaudiana. It is not consumed directly as a food ingredient but is the primary active metabolite after intestinal hydrolysis of steviol glycosides by gut microbiota.

**Macronutrients:** Negligible caloric value; no meaningful contribution of carbohydrates, fats, or proteins at physiologically relevant doses. Caloric contribution is effectively zero.

**Micronutrients:** Not a source of vitamins or minerals in functional quantities.

**Bioactive Compounds:**
- Steviol itself (ent-13-hydroxykaur-16-en-18-oic acid): the active diterpene aglycone; present at trace systemic concentrations following glycoside ingestion.
- Exhibits structural similarity to gibberellins (plant growth hormones), which may underlie some bioactive effects.
- In vitro concentrations used in cancer/anti-inflammatory studies typically range from 10–200 µM, which may not be physiologically achievable through dietary intake alone.

**Bioavailability Notes:**
- Steviol glycosides are poorly absorbed intact in the small intestine; colonic bacteria (e.g., Bacteroides, Clostridium) cleave glycosidic bonds to release steviol.
- Steviol is absorbed in the colon, conjugated to steviol glucuronide in the liver, and excreted renally.
- Systemic plasma concentrations of steviol after typical steviol glycoside intake are low (nanomolar to low micromolar range), limiting translation of high-dose in vitro findings to in vivo efficacy.
- No dietary reference intake or established safe upper limit exists for pure steviol as an isolated compound.

Preparation & Dosage

Clinically studied doses include 250 mg stevioside three times daily for 3 months. The acceptable daily intake (ADI) for steviol glycosides is 4 mg/kg body weight as steviol equivalents. No direct steviol dosing has been established in human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Chromium picolinate, alpha-lipoic acid, cinnamon extract, gymnema sylvestre, bitter melon extract

Safety & Interactions

Steviol glycosides are generally recognized as safe (GRAS) by the FDA at acceptable daily intakes of up to 4 mg/kg body weight (as steviol equivalents), but steviol itself as an isolated compound has a less established direct safety profile. Because stevioside can lower blood pressure and enhance insulin secretion, concurrent use with antihypertensives or antidiabetic drugs (e.g., metformin, sulfonylureas) may produce additive hypotensive or hypoglycemic effects requiring dose monitoring. Steviol has shown genotoxic potential in some in-vitro bacterial assay models (Ames test), though this has not been replicated in mammalian systems at physiological doses. Pregnant and breastfeeding women are advised to limit intake, as reproductive safety data for isolated steviol specifically remain insufficient.